When comparing PSMA-PET/CT-guided biopsy with MRI-guided biopsy, the authors found that PSMA-PET/CT-guided biopsy led to a 3% increase in csPCa detection and a 1% decrease in the detection of non-clinically significant prostate cancer and was non-inferior to mpMRI [111]. This evidence concerns the gene FOLH1 and Familial prostate cancer.